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ABSTRACT  
 
Objective: Grip strength is a well-characterized measure of weakness and of poor muscle 
performance, but there is a lack of consensus on its prognostic implications in terms of 
cardiac adverse events in patients with cardiac disorders. 
Methods: Articles were searched in PUBMED, the Cochrane Library, BioMed Central and 
EMBASE. Main inclusion criteria were: patients with cardiac disorders (ischemic heart 
disease [IHD], heart failure [HF], cardiomyopathies, valvulopathies, arrhythmias); evaluation 
of grip strength by handheld dynamometer; relation between grip strength and outcomes. 
Endpoints of the study were cardiac death, all-cause mortality, hospital admission for HF, 
cerebrovascular accident (CVA) and myocardial infarction (MI). Data of interest were 
retrieved from the articles and after contact with authors and then pooled in an individual 
patient meta-analysis. Univariate and multivariate logistic regression was performed to define 
predictors of outcomes.  
Results: Overall, 23480 patients were included from 7 studies. Mean age was 62.36.9 years 
and 70% were male. The mean follow-up was of 2.82±1.7 years. After multivariate analysis 
grip strength [difference of 5 Kg, 5xKg] emerged as an independent predictor of cardiac 
death (OR 0.84; 95%CI 0.79-0.89; p<0.0001), all-cause death (OR 0.87, 95%CI 0.85-0.89; 
p<0.0001) and of hospital admission for HF (OR 0.88, 95%CI 0.84-0.92; p<0.0001). On the 
contrary, we did not find any relationship between grip strength and occurrence of MI or 
CVA.  
Conclusions: In patients with cardiac disorders, grip strength predicted cardiac death, all-
cause death and hospital admission for HF.  
Meta-analysis registration: The protocol of this meta-analysis is registered in PROSPERO 
(CRD42015025280). 
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KEY QUESTIONS 
What is already known about this subject? 
 There is a great interest in the assessment of frailty and/or physical performance in 
cardiac patients.  
 Grip strength is an indicator of overall muscle function. 
 The measurement of grip strength is simple, fast, cost-effective and can be performed 
also in bedridden patients. 
What does this study add? 
 Every 5 kg decrease of grip strength emerged as an independent predictor for cardiac 
death, hospital admission for heart failure and all-cause death in patients with cardiac 
disorders. 
How might this impact on clinical practice? 
 The systematic application of grip strength in the evaluation and management of 
cardiac patients might help physicians in the clinical decision-making process. 
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INTRODUCTION 
 
In recent years, the mean age of cardiac patients has progressively increased. Accordingly, 
the issue of frailty is becoming pivotal for cardiologists. Frailty significantly affects clinical 
outcomes (including all-cause mortality), quality of life and the economic burden associated 
with healthcare [1-3]. In daily clinical practice, frailty can be assessed with several tests. 
Sarcopenia and low muscle strength are key elements of the frailty syndrome. Thus, it is not 
surprising that grip strength, an excellent indicator of overall muscle function [4], is part of 
many frailty diagnostic algorithms. Its predictive role in the general population on all-cause 
mortality has been already tested [5], showing that higher grip strength is associated with 
lower mortality. Previous studies have shown that grip strength strictly depends on age, sex, 
body size, muscle mass, socioeconomic status and level of physical activity [6-7]. It may be 
negatively influenced by chronic disease and nutritional status [6]. The large majority of 
previous studies on grip strength were not focused on cardiac patients [8-14]. Reliable data 
about the predictive role of grip strength in a cardiac population on cardiac endpoints (cardiac 
death, myocardial infarction, hospital admissions for heart failure) is not available.  
Thus, the aim of this individual patient pooled meta-analysis is to investigate the prognostic 
value of grip strength, especially for cardiac mortality, in patients with cardiac disease.  
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METHODS 
 
We developed a systematic review and individual patient pooled meta-analysis following 
Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) amendment 
to the Quality of Reporting of Meta-analyses (QUOROM) statement [15-16]. The protocol 
for this study was previously published on an international prospective register for systematic 
reviews (PROSPERO) with the number: CRD42015025280. 
 
Search strategy 
The search strategy was elaborated by RP in August 2016. The terms searched were ((grip 
strength) OR (handgrip)) AND ((cardiac death) OR ((cardiac) AND ((death) OR (mortality))) 
OR (myocardial infarction) OR (acute coronary syndrome) OR (ST elevation myocardial 
infarction) OR (STEMI) OR (heart failure) OR (revascularization) OR (percutaneous 
coronary intervention) OR (PCI) OR (cardiac disease) OR (coronary artery disease)). The 
databases analyzed were from PUBMED, Biomed Central, Cochrane library and EMBASE. 
Only papers published in English and in peer-reviewed journals were selected. Two 
independent reviewers (GB, ET) analyzed the records and decided which deserved full-text 
analysis. In case of disagreement between the reviewers a third independent reviewer (MS) 
was involved to discuss the disagreement and take the final decision. 
 
Selection criteria 
The inclusion criteria for the studies were: i) observational or clinical trials with a relation 
between grip strength and cardiac outcome, ii) evaluation of grip strength by handheld 
dynamometer. The above-mentioned search strategy was designed to address these two main 
criteria. Nevertheless, our aim was to focus the attention on patients with cardiac disorders. 
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Then, we defined ischemic heart disease (IHD), heart failure (HF), cardiomyopathies, 
valvulopathies, arrhythmias as cardiac diseases of interest. Independent reviewers (GB, ET) 
analyzed all items generated by the search strategy and selected only those satisfying the third 
inclusion criteria: iii) study population affected by major cardiac disease. We included only 
data from patients showing one of these diseases at the time of the inclusion in the original 
study. Exclusion criteria were: i) duplicate reports; ii) duplicate of the sample population; iii) 
case reports/series iv); reviews or meta-analyses; v) lack of outcome of interest; vi) 
population without major cardiac disease; vii) cross-sectional studies. The same reviewers 
(GB, ET) independently analyzed the references of all the evaluated articles to avoid the 
eventual exclusion of additional studies. All the authors agreed on the final number of studies 
included. 
 
Data abstraction, contact with authors, endpoints 
The reviewers (GB, ET, MS) completed a database with data regarding: the journal, year of 
publication, hospital center, population characteristics, grip strength value, outcomes of 
interest. After selection of papers, corresponding authors were contacted and invited to share 
individual patient data. The following variables were asked: age, sex, anthropometric 
measurements (weight, height, body mass index [BMI)], cardiac risk factors (smoking habit, 
hypertension, diabetes, dyslipidemia), cardiac disease at the time of the inclusion in the study 
(IHD, HF, cardiomyopathies, valvulopathies, arrhythmias), comorbidities (chronic 
obstructive pulmonary disease [COPD], peripheral artery disease (PAD), chronic kidney 
disease [CKD], cerebrovascular accident [CVA]), grip strength expressed in Kg and 
outcomes of interest. The primary outcome of the study was cardiac death. Secondary 
outcomes were all-cause mortality, hospital admission for HF, myocardial infarction (MI) 
and CVA. Data obtained from each study were firstly checked against reported results and 
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queries were resolved with the corresponding authors. Data were assessed in a consistent 
manner across all studies with standard definitions and parameters.  
 
Internal validity and quality appraisal  
Two unblinded reviewers (RP, MS) independently evaluated the quality of the included 
studies using a modified version of the Newcastle-Ottawa Scale (NOS) for cohort studies 
[17] (Table 1s). Because of the design of the studies considered, the section “Comparability” 
and question 2 of the section “Selection” (“selection of the non-exposed cohort”) have not 
been considered [18]. Discrepancies between reviewers have been solved by consensus. No 
study was excluded on the basis of this analysis. The maximum score obtained was 6 and the 
minimum 5 (Table 1s). 
 
Data analysis and synthesis 
Demographics and other baseline characteristics were summarized in terms of mean ± 
standard deviation (SD) for continuous variables (normal distribution assessed by 
Kolmogorov-Smirnov test). Categorical variables were expressed as absolute (number of 
participants) and relative frequencies (percentage). Variables were compared using the t-test 
for independent groups and the Chi-squared test as appropriate. Among the required 
variables, the following were available and considered in the present analysis: age, sex, 
weight, height, BMI, smoking habit, hypertension, IHD, COPD, CVA, grip strength. 
Additional information is detailed in Table 2s. To overcome potential limitation due to 
reproducibility of the test, grip strength was analysed as a 5 kg difference (5xKg). Univariate 
logistic regression was performed to evaluate the relationship between variables and 
outcomes (Table 3s). All the variables with a p value ≤0.05 at univariate analysis were 
entered into the multivariate model for assessing independent predictors of outcomes. To 
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establish the ability of grip strength to discriminate the primary outcome, receiver operating 
characteristics (ROC) curve with area under the curve (AUC) was also calculated. As 
suggested by recent consensus document, we stratified the analysis according to sex (male vs. 
female) [19] and age of the population (<65 years old vs. ≥ 65 years old). Using Youden’s 
index (J), the best cut-off (c) point for grip strength was obtained, by the formula J= 
maxc {Sensibility (c) + Specificity (c) − 1} [20]. The OR for the relationship between grip 
strength and cardiac death, all-cause death and hospital admission for heart failure was 
calculated for each single study and then pooled using the Mantel Haenszel method, with a 
random-effects method, and the generic inverse variance approach [21]. The weight of the 
individual studies was measured as the inverse of the estimated variance of the log odds ratio 
[21-22]. Heterogeneity across the trials has been assessed using the I2 statistics, with a value 
of 0-24.9% considered insignificant, 25-49.9% mild, 50-74.9% moderate and 75% 
considered severe [23]. Publication bias was appraised by Begg and Mazumdar rank 
correlation [23]. A p value <0.05 was considered statistically significant. Prometa software 3 
(Internovi, Cesena, Itay), RevMan 5 (The Cochrane Collaboration, The Nordic Cochrane 
Centre, Copenhagen, Denmark) and SPSS version 21 (IBM, Italy) were the software used for 
statistical analyses.  
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RESULTS 
 
Search strategy 
A total of 2998 records were analyzed. After a first evaluation, 63 records were screened and 
of these 35 were excluded for different reasons (Figure 1). Twenty-eight full-texts were 
assessed for eligibility, but 1 was excluded because it was a duplicate, 2 had no data on 
outcomes, 4 were not focused on patients with major cardiac disease, 1 was a comment on 
another study. Therefore, 20 corresponding authors were contacted (Table 4s). Seven (35%) 
Authors agreed to share data [8-14] and the study populations of their studies were included 
in the individual patient pooled meta-analysis [8-14] (Figure 1, Table 1). 
 
Population characteristics 
Overall, the final study population included 23480 patients (Table 2). Mean age was 62.36.9 
years and 70% were male. At the inclusion in the study, 49.5% patients were affected by 
IHD. A detailed description of anthropometric measurements, risk factors and comorbidities 
is reported in Table 2.  
 
Primary outcome 
After a mean follow-up of 2.82±1.7 years, cardiac death occurred in 523 (2.2%) patients. As 
expected, age and comorbidities significantly differed between patients who died or not for 
cardiac cause (Table 2). IHD was more frequent in patients with CD (3% vs. 2%, p<0.001). 
Mean grip strength of patients who experienced CD was 2712 kg vs. 3111 kg in those 
survived (p<0.0001). After multivariable analysis, grip strength (as 5xKg) emerged as 
independent predictor of cardiac death (OR 0.84; 95%CI 0.79-0.89; p<0.0001), together with 
age (OR 1.10; 95%CI 1.08-1.12; p<0.0001), male sex (OR 2.19; 95%CI 1.58-3.04; 
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p<0.0001), ischemic heart disease (OR 2.01; 95%CI 1.61-2.51; p<0.0001), hypertension (OR 
3.01; 95%CI 2.10-4.32; p<0.0001), COPD (OR 1.46; 95%CI 1.05-2.05; p=0.025) and 
previous CVA (OR 7.4; 95%CI 5.62-9.79; p<0.0001). ROC curve analysis confirmed the 
ability of grip strength to discriminate cardiac death. The AUCs were: 0.61 (95%CI 0.56-
0.66, p<0.001) for male <65 years old, 0.63 (95%CI 0.53-0.73, p=0.025) for female <65 
years old, 0.65 (95%CI 0.61-0.69, p<0.001) for male ≥65 years old and finally 0.74 (95%CI 
0.64-0.74, p<0.0001) for female ≥65 years old (Figure 1s-4s, table 5s). In the same four 
subgroups, the best cut-offs were 39, 24, 31 and 19 Kg, respectively (Figure 1s-4s, table 5s). 
 
Secondary outcomes 
The secondary outcomes all-cause mortality, hospital admission for HF, MI and 
cerebrovascular accident occurred in 2206 (9.4%), 884 (3.7%), 1010 (4.3%) and 63 (0.3%) 
patients, respectively. As reported in Table 3, grip strength (as 5xKg) emerged as an 
independent predictor of all-cause mortality (OR 0.87, 95%CI 0.85-0.89; p<0.0001) and of 
hospital admission for HF (OR 0.87, 95%CI 0.84-0.92; p<0.0001) (Table 3). On the contrary, 
we did not find any relationship between grip strength and occurrence of MI or CVA (Table 
3).  
 
Study-level meta-analysis 
The analysis on aggregate data confirmed grip strength (for 5xKg change) as a predictor of 
cardiac death (OR 0.83, 95% CI 0.74-0.94, I249%) (Figure 2). Similarly, grip strength was 
significantly associated with all-cause death and with the occurrence of hospital admission 
for HF (OR 0.86, 95% CI 0.81-0.91, I2 18%; and OR 0.89, 95% CI 0.82-0.96, I2 19%; 
respectively) (Figures 3-4). Of note the heterogeneity, expressed as I2 degree, for cardiac 
death was mild and it was insignificant for all-cause death and hospital admission for HF. 
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The analysis showed the absence of publication bias (Z value for Kendall’s tau -0.94; -0.75; -
0.68 with p 0.35; 0.45; 0.50 for cardiac death, all-cause death and hospital admission for heart 
failure, respectively).   
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DISCUSSION 
 
The main finding of this individual patient pooled meta-analysis is that grip strength is 
predictive of cardiac death and of hospital admission for heart failure in a population of 
patients with cardiac disease (mainly ischemic heart disease or heart failure). 
In agreement with previous study [7], grip strength was also predictive of all-cause death.  
A recent consensus document suggested grip strength as a tool to discriminate clinically 
relevant weakness [19]. The clinical implication of relevant weakness is of paramount 
importance because it is associated with a significant increase in mortality. The consensus 
document suggested different cut-offs according sex (male vs. female). Our findings 
confirmed the main results of the consensus document. After stratification of the study 
population according to sex (male vs. female) and age (<65 vs. ≥65 years), we identified best 
cut-offs consistent with those suggested for the identification of clinically relevant weakness 
[19]. Our ROC curve analysis found a best cut-off point of 31 Kg for male and of 19 Kg for 
female in subjects aged ≥65, while the cut-offs were higher (24 for female and 39 for male) 
for younger patients (aged< 65 years) as expected. We focused our attention in a large 
population of patients with cardiac disease where the predictive role of grip strength is 
assessed in terms of cardiac endpoints. We confirmed that grip strength is associated with 
mortality (all-cause and cardiac) in patients with cardiac disorders. Heart failure seems to 
play a major role in this association. It is well known that patients with HF are often affected 
by cachexia, weakness and frailty [8]. In our study the average BMI was 29 kg/m2 and thus 
in the overweight range. This finding might suggest that overweight and obesity may mask 
sarcopenia and weakness. Therefore, only a more direct measure of muscle weakness (e.g. 
grip strength) can improve the identification of subjects at higher risk of hard events.  
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There is a great interest in the assessment of frailty in cardiac patients [1]. This clinical need 
is mainly related to the increased number of frail patients that usually are also older [1]. The 
prevalence of HF reaches 10% among patients aged 70 years and older [24]. The prevalence 
of frail patients affected by HF is expected to increase, because of the spread of invasive 
procedures, starting from cardiac revascularization to the percutaneous procedures for the 
treatment of valvular disease [25]. Frailty syndrome includes weakness, slowness, low level 
of physical activity, low energy or self-reported exhaustion and unintentional weight loss 
[26]. Frailty is a geriatric syndrome that reflects a state of decreased physiological reserve 
and increased vulnerability to stress [26]. In daily clinical practice, the decision between a 
highly invasive approach and a more conservative treatment strategy, are mainly based on 
scores like The European System for Cardiac Operative Risk Evaluation (EuroSCORE) II 
and Society of Thoracic Surgeons (STS) [27]. Both these scores are tailored on clinical 
variables mainly related to the presence of comorbidities (e.g. age, PAD, creatinine clearance, 
chronic lung disease, previous cardiac surgery, left ventricle ejection fraction, pulmonary 
intervention, etc.). Despite the availability of several standardised measures of physical 
strength and mobility, only one item of these scores is related to an approximate description 
of the functional status (e.g. severe impairment of mobility secondary to musculoskeletal or 
neurological dysfunction) [27] without a specification of the kind of test to be used. The 
major drawback for the daily application of the scales assessing physical performance is that 
they tend to be too long and complex [28]. They require a specific preparation, a dedicated 
staff and are time-consuming. Grip strength, as well as other scales, show several limitations. 
Nevertheless, it has the strong advantage to be easy, user-friendly and quick. In addition, it 
can be performed also in bedridden patients [29]. Thus, grip strength may be an optimal first 
choice in the attempt to introduce the assessment of physical performance in the clinical 
decision-making process of patients with cardiac disorders. Obviously, these speculations 
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need confirmation and future randomized-controlled clinical trials are clearly in demand [28]. 
Grip strength is a well characterized measure of weakness and poor muscle performance. 
Grip strength measures the strength of contraction of the flexor muscles of the 
fingers/forearm through the use of a dynamometer [5]. From the literature, it is known as 
such index correlates with the nutritional status of subjects and their capacity for functional 
recovery post-surgery [26]. In the Prospective Urban-Rural Epidemiology (PURE) study, a 
large, longitudinal population study, during a median follow-up of 4 years and in a population 
of 142861 recipients, grip strength was a stronger predictor of all-cause and cardiac mortality 
than systolic blood pressure [30]. It also showed that every 5 kg decline in grip strength was 
associated with a 7% increased risk of heart attack, and a 9% higher risk of stroke. The 
present individual patient pooled meta-analysis included 23481 patients affected by cardiac 
disorders, confirming that grip strength is a good predictor of cardiac death and hospital 
admission for heart failure, as well as of all cause death. We are not able to confirm the 
association with MI and CVA. The population enrolled in the PURE study was bigger. We 
may not exclude that a larger prospective study on cardiac patients may give different results. 
At the same time, we cannot define the mechanism behind these associations. We may 
suppose that endothelial dysfunction, arterial stiffness and autonomic imbalance might 
mediate the association between muscle strength and cardiovascular events [30]. 
Nevertheless, further research is needed to solve this issue.  
 
Study limitation 
This is an individual patient pooled meta-analysis and data were obtained retrospectively by 
each corresponding author. For this reason, bias related to incomplete data reporting cannot 
be excluded. Exclusion criteria of patients were different among studies. We cannot exclude 
the presence of bias related to the inclusion of patients with arthritis or invaliding stroke for 
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all the study involved (Table 1). It is important to highlight that the large part of the patients 
included in the current analysis was retrieved from the study of Celis-Morales [12]. The 
analysis of the heterogeneity showed a mild degree for cardiac death and an insignificant 
degree for all-cause death and hospital admission for heart failure. Then, the overall 
consistency of our analyses and findings is good and we may suppose that the mild degree of 
heterogeneity is mainly related to the different way to adjudicate cardiac death between trials 
(Table 1). The multivariate analysis in each single study was slightly modified, based on the 
clinical variables available for each single study (Table 2s). Finally, it was not possible to 
perform a pooled survival analysis because data about time-to-event were not available for 
each single patient.  
 
Conclusions 
Grip strength emerged as independent predictor for cardiac death, all-cause death and 
hospital admission for heart failure in patients with cardiac disorders. In the context of a 
comprehensive clinical evaluation process, grip strength can support the clinical decision-
making process.   
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FIGURE LEGEND 
 
Figure 1: Outline of the search strategy 
 
Figure 2: Forest plot of the relationship between grip strength (5xKg) and cardiac 
death.  
Data are displayed as OR (95% CI). CI: confidence interval.  
 
Figure 3: Forest plot of the relationship between grip strength (5xKg) and all-cause 
death.  
Data are displayed as OR (95% CI). CI: confidence interval. 
 
Figure 4:  Forest plot of the relationship between grip strength (5xKg) and hospital 
admission for heart failure.  
Data are displayed as OR (95% CI). CI: confidence interval. HF: heart failure. 
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Table 1: Studies included in the meta-analysis 
 
References Pts 
Geographic 
area 
Time and type 
of the 
enrolment 
Exclusion criteria 
Source for documentation of 
events 
CD definition 
Major cardiac disease 
at the inclusion in the 
study 
FU in 
days 
Grip strength 
Celis-
Morales et 
al.  
2016 
22219 England and 
Wales 
April 2007 -
December 
2010 
Prospective 
NS. Some patients did not perform 
grip strength because of undefined 
illness. 
Death certificates 
Hospital admission identified via 
record linkage to health episode 
statistics records 
ICD 10 codes I21, I21.4 
and I21.9. 
Ischemic heart disease 
and heart failure as 
defined by the ICD 10 
codes I21, I21.4 and 
I21.9 
1538 
±566 
Jamar J001005 hydraulic 
hand dynamometer, mean of 
the right-hand and left-hand 
values, expressed as kg. 
 
Colin-
Ramirez et 
al. 
2012 
396 Mexico NS 
Retrospective 
Uncontrolled thyroid disorders, 
hepatic failure, suspicion of 
tumoral activity, limb 
amputations, or ischemic heart 
disease susceptible to 
revascularization. 
 
Heart failure clinical registry and 
medical records 
Sudden, progressive HF, 
cardiac arrhythmias, stroke, 
or myocardial infarction 
death. 
 
HF: decreased systolic 
and diastolic function 
determined at the 
echocardiography 
1332±700 Smedley Hand 
Dynamometer. Dominant 
hand. The measurements 
were repeated twice, and the 
highest score was recorded 
in kilograms. 
 
Izawa et al. 
200.  
147 Kawasaki, 
Japan 
September 
1999 - July 
2006 
Prospective 
Heart Association functional class 
IV, neurologic, peripheral vascular, 
orthopedic, or pulmonary disease. 
 
Inpatients medical records Sudden cardiac death, 
progressive heart failure. 
HF: LVEF<45% 495±173 Handle Jamar dynamometer. 
Average of the highest value 
of the right + left side 
handgrip strength/ 2. The 
highest value measured was 
considered the index of 
handgrip strength.  
 
Izumiya et 
al. 
2016 
119 Kumamoto, 
Japan 
March 2012 -
April 2013 
Retrospective 
Acute coronary syndrome, 
malignant tumors, acute 
infection, chronic hemodialysis 
and inflammatory diseases. 
Medical records Death related to HF events. HF: clinical diagnosis 
according to typical 
symptoms and signs 
337±233 Handgrip strength 
dynamometer. Two 
measurements of grip 
strength of the dominant 
hand, the higher value of the 
two measurements was used  
 
Macdonald 
et al. 
2016 
145 Sydney, 
Australia 
From March 
2013 
Prospective 
Because already received 
ventricular assist device or heart 
transplantation. 
NS NA HF: advanced heart 
failure NYHA III or IV 
365 Jamar dynamometer. 
Standard protocol was 
followed as described by the 
American Society of Hand 
Therapy. 
 
McNallan et 
al. 
2013 
224 Minnesota, 
USA 
From 2007-
2011 
Prospective 
NS Rochester Epidemiology project 
Medical records, death 
certificates 
CD and non-CD death 
defined according AHA 
categories 
HF diagnosis via 
Framingham criteria 
700±123 Jamar dynamometer 
Sanchis et 
al. 
2014 
330 Valencia, 
Spain 
October 2010 - 
February 2012 
Prospective 
Surgical patients. outpatients’department 
direct contact, 
general physician 
regional registry of mortality 
CD was defined as death 
attributed to cardiac cause 
or unknown cause. 
IHD: acute coronary 
syndrome. 
1788±90 Hand-held isometric 
dynamometer 
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Pts: number of patients in the study. CD: cardiac death. FU: follow-up. HF: heart failure. NS: not specified. ICD: international classification of diseases. 
LVEF: left ventricle ejection fraction. NYHA: New York Heart Association. AHA: American Heart Association. ECG: electrocardiogram.
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Table 2: Study population characteristics  
 
 
All 
(n=23480) 
CD 
(n=523) 
free from CD 
(n=22957) 
p1 
all-cause death  
(n=2206) 
free from all-cause 
death 
(n=21274) 
p2 
Hospitalized 
for HF 
(n=887) 
free from HF 
(n=22370) 
p3 
           
Age, years 62.3±6.9 68.5±10 62.2±7 < 0.0001 65±8 62±7 <0.0001 63±10 62±7 0.08 
Male, n. (%) 16540 (70) 395 (2) 16045 (98) 0.010 1704 (10) 14836 (90) < 0.0001 717 (33) 15688 (67) < 0.0001 
Height, cm 169±9 168±10 169±9 0.001 169±9 169±9 0.769 168±9 169±9 0.156 
Weight, Kg 84±16.8 81±20 84±16 0.001 84±18 84±16 0.937 82±21 84±17 0.008 
BMI, Kg/m2 29±5 29±6 29±5 0.032 29±6 29±5 0.681 28±6 29±5 0.003 
           
Risk factors, n. (%)           
Hypertension 1267 (5) 148 (13) 992 (87) < 0.0001 308 (24) 959 (76) < 0.0001 210 (20) 857 (80) < 0.0001 
Current or former smoker 14091 (60) 263 (2) 13828 (98) 0.001 1443 (10) 12648 (90) < 0.0001 378 (3) 13690 (97) 0.322 
           
Cardiac disease at the inclusion, n (%)           
IHD 11619 (49.5) 335 (3) 11243 (97) < 0.0001 1330 (11) 10289 (89) < 0.0001 514 (4) 11105 (96) < 0.0001 
           
Comorbidities, n. (%)            
COPD 1260 (5.4) 61 (5) 1199 (95) < 0.0001 252 (20) 1008 (80) < 0.0001 66 (5) 1145 (95) < 0.0001 
Previous CVA 553 (2.4) 89 (16) 464 (84) < 0.0001 148 (27) 405 (73) < 0.0001 33 (6) 520 (94) < 0.0001 
           
Grip strength, Kg  31±11 27±12 31±11 < 0.0001 29±11 31±11 < 0.0001 30±11 31±11 0.189 
           
 
CD: cardiac death. HF: heart failure. BMI: body mass index. IHD: ischemic heart disease. COPD: chronic obstructive pulmonary 
disease. CVA: cerebrovascular accident. 
p1: for the comparison between patients reaching or not the endpoint CD. p2: for the comparison between patients reaching or not the 
endpoint all-cause death. p3: for the comparison between patients reaching or not the endpoint hospital admission for HF.  
 29 
Table 3:  Multivariate logistic regression (individual patient pooled meta-analysis) 
 
 Cardiac death All-cause death Admission for HF Myocardial infarction Cerebrovascular accident 
 OR 95%CI p OR 95%CI p OR 95%CI p OR 95%CI p OR 95%CI p 
                
Age 1.10 1.08-1.12 <0.001 1.06 1.06-1.08 <0.001 1.04 1.02-1.05 <0.001 1.01 1-1.02 0.001 1.11 1.06-1.16 <0.001 
Male 2.19 1.58-3.04 <0.001 2.21 1.9-2.55 <0.001 3.2 2.5-4.08 <0.001 2.05 1.67-2.52 <0.001 -- -- -- 
BMI 0.86 0.73-1.02 0.083 -- -- -- 0.88 0.84-1.02 0.233 -- -- -- -- -- -- 
                
Hypertension 3.01 2.10-4.32 <0.001 1.78 1.42-2.23 <0.001 2.83 2.12-3.79 <0.001 2.38 1.79-3.18 <0.001 2.88 1.16-7.10 0.02 
Smoking habitus 1.24 0.99-1.56 0.061 1.67 1.5-1.87 <0.001 -- -- -- 1.17 1.02-1.34 0.026 0.94 0.51-1.71 0.831 
                
IHD 2.01 1.61-2.51 <0.001 1.63 1.48-1.80 <0.001 1.47 1.26-1.73 <0.001 1.39 1.21-1.59 0.041 1.99 1.08-3.57 0.020 
COPD 1.46 1.05-2.05 0.025 1.96 1.67-2.31 <0.001 1.47 1.12-1.93 <0.001 -- -- -- 2.4 1.18-4.5 0.016 
Previous CVA 7.4 5.62-9,79 <0.001 2.95 2.40-3.60 <0.001 1.29 0.88-1.88 0.877 1.52 1.10-2.11 0.011 -- -- -- 
                
Handgrip 5x 0.84 0.79-0.89 <0.001 0.87 0.85-0.89 <0.001 0.88 0.84-0.92 <0.001 0.96 0.92-1 0.06 0.94 0.83-1.07 0.377 
                
 
HF: heart failure. BMI: body mass index. IHD: ischemic heart disease. COPD: chronic obstructive pulmonary disease. CVA: 
cerebrovascular accident 
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